CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.
Fiche publication
Date publication
juin 2018
Journal
Investigative ophthalmology & visual science
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARBAR Christian, Pr LABROUSSE Marc, Dr BOULAGNON-ROMBI Camille, Pr BENSUSSAN Armand
Tous les auteurs :
Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C
Lien Pubmed
Résumé
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic therapies. The aim of the present study was to assess the distribution of CD160 in the human eye, and to search for a possible correlation with retinal neovascular diseases.
Mots clés
Actins, metabolism, Aged, Antigens, CD, metabolism, Biomarkers, metabolism, Ciliary Body, metabolism, Conjunctiva, metabolism, Endoglin, metabolism, Endothelium, Vascular, metabolism, Epithelial Cells, metabolism, Female, GPI-Linked Proteins, metabolism, Humans, Macrophages, metabolism, Male, Middle Aged, Receptors, Immunologic, metabolism, Retinal Ganglion Cells, metabolism, Retinal Neovascularization, metabolism, Retinal Vessels, metabolism, Retrospective Studies, Tissue Donors, Transcriptional Regulator ERG, metabolism
Référence
Invest. Ophthalmol. Vis. Sci.. 2018 Jun 1;59(7):2679-2686